ANI announced that the Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for Oxycodone HCl Capsules.  

Oxycodone HCl is a Schedule II substance indicated for the management of moderate to severe acute and chronic pain where the use of an opioid analgesic is appropriate. Oxycodone HCl is a pure agonist opioid that has multiple actions qualitatively similar to those of morphine. The most prominent of these involves the central nervous system and organs composed of smooth muscle.

RELATED: FDA Announces Major Labeling Changes for Opioids

Oxycodone HCl Capsules will be available in a 5mg strength. 

For more information call (800) 434-1121 or visit AniPharmaceuticals.com.